Related Experiment Video

Updated: Aug 17, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

Micafungin: the US perspective

Aimee K Zaas1, William J Steinbach

  • 1Duke University Medical Center , Department of Medicine, Division of Infectious Diseases and International Health, Durham, NC 27710, USA. aimee.zaas@duke.edu

Expert Review of Anti-Infective Therapy
|May 28, 2005
PubMed

Insights

Micafungin is a new antifungal drug effective for treating candidiasis and aspergillosis. It shows promise for first-line treatment and preventing fungal infections in high-risk patients.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) contribute significantly to morbidity and mortality, particularly in hospital settings and immunocompromised individuals.
  • Candida species and Aspergillus species are the most prevalent causes of IFIs, with Candida bloodstream infections ranking as the fourth most common in the USA.
  • Existing antifungal drug classes include polyenes, antimetabolites, allylamines, azoles, and echinocandins.

Purpose of the Study:

  • To evaluate the safety and efficacy of micafungin, an echinocandin antifungal agent.
  • To assess micafungin's potential as a treatment for candidiasis and aspergillosis.
  • To explore micafungin's utility in prophylaxis against IFIs during neutropenia.

Main Methods:

  • Clinical trials were conducted in Japan, Europe, and South Africa.
  • Safety and efficacy data were collected for micafungin treatment.
  • Patient populations included those with candidiasis, aspergillosis, and neutropenia.

Main Results:

  • Micafungin demonstrated safety and efficacy in clinical trials for treating candidiasis and aspergillosis.
  • The drug was approved by the U.S. Food and Drug Administration in March 2005.
  • Micafungin showed potential for first-line treatment of candidiasis.

Conclusions:

  • Micafungin is a safe and effective option for treating invasive candidiasis and aspergillosis.
  • It offers a promising therapeutic choice for candidiasis and prophylaxis in high-risk neutropenic patients.
  • The drug expands treatment options within the echinocandin class for serious fungal infections.

More Related Videos

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...